

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

Monoclonal Mouse Anti-Human Ki-67 Antibody

RRID:AB_2687921

Type: Antibody

Proper Citation

Agilent Cat# GA626, RRID:AB_2687921

Antibody Information

URL: http://antibodyregistry.org/AB_2687921

Proper Citation: Agilent Cat# GA626, RRID:AB_2687921

Target Antigen: Ki-67

Host Organism: mouse

Clonality: monoclonal

Comments: Original Manufacturer: Dako. Now part of Agilent.

Antibody Name: Monoclonal Mouse Anti-Human Ki-67 Antibody

Description: This monoclonal targets Ki-67

Target Organism: human

Clone ID: MIB-1

Antibody ID: AB_2687921

Vendor: Agilent

Catalog Number: GA626

Alternative Catalog Numbers: GA62661-2

Record Creation Time: 20231110T034040+0000

Record Last Update: 20260829T124103+0000

Ratings and Alerts

No rating or validation information has been found for Monoclonal Mouse Anti-Human Ki-67 Antibody.

No alerts have been found for Monoclonal Mouse Anti-Human Ki-67 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Ishida M, et al. (2026) AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. NPJ precision oncology, 10(1).

de Groot AF, et al. (2025) Ribociclib-Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01). Clinical cancer research : an official journal of the American Association for Cancer Research, 31(15), 3175.

Kang N, et al. (2025) Exploring B7-H4's Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities. Molecular cancer research : MCR, 23(4), 327.

Stacchiotti S, et al. (2024) GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(22), 5122.

Jotanovic J, et al. (2024) Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors. Acta neuropathologica, 148(1), 68.

Cammarata FP, et al. (2023) Proton boron capture therapy (PBCT) induces cell death and mitophagy in a heterotopic glioblastoma model. Communications biology, 6(1), 388.

Dayton TL, et al. (2023) Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites. Cancer cell, 41(12), 2083.

Dittrich T, et al. (2022) A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myeloma. Cell reports methods, 2(11), 100322.

Villanueva H, et al. (2022) Characterizing treatment resistance in muscle invasive bladder cancer using the chicken egg chorioallantoic membrane patient-derived xenograft model.

Heliyon, 8(12), e12570.

Hagege A, et al. (2022) Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma. Cell reports. Medicine, 3(9), 100659.

Gonzalez H, et al. (2022) Cellular architecture of human brain metastases. Cell, 185(4), 729.

Piao J, et al. (2021) Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01. Cell stem cell, 28(2), 217.

Bolaender A, et al. (2021) Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system. Nature communications, 12(1), 4669.

Tozzi M, et al. (2020) Proton Pump Inhibitors Reduce Pancreatic Adenocarcinoma Progression by Selectively Targeting H⁺, K⁺-ATPases in Pancreatic Cancer and Stellate Cells. Cancers, 12(3).

Kanzawa M, et al. (2020) Adrenal Corticomedullary Mixed Tumor Associated With the FGFR4-G388R Variant. Journal of the Endocrine Society, 4(9), bvaa101.

Salvador-Barbero B, et al. (2020) CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. Cancer cell, 37(3), 340.

Li YJ, et al. (2019) Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme. Cell chemical biology, 26(2), 278.

Ogiwara H, et al. (2019) Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers. Cancer cell, 35(2), 177.